RVC - Polymer Plate for improved biomedical analyses by tissue imaging MALDI-TOF

Information

  • Research Project
  • 8591704
  • ApplicationId
    8591704
  • Core Project Number
    R43GM108234
  • Full Project Number
    1R43GM108234-01
  • Serial Number
    108234
  • FOA Number
    PA-11-215
  • Sub Project Id
  • Project Start Date
    9/16/2013 - 11 years ago
  • Project End Date
    3/15/2014 - 10 years ago
  • Program Officer Name
    SHEELEY, DOUGLAS
  • Budget Start Date
    9/16/2013 - 11 years ago
  • Budget End Date
    3/15/2014 - 10 years ago
  • Fiscal Year
    2013
  • Support Year
    01
  • Suffix
  • Award Notice Date
    9/16/2013 - 11 years ago

RVC - Polymer Plate for improved biomedical analyses by tissue imaging MALDI-TOF

DESCRIPTION: The objective of this proposal is to attempt a new mode of analysis for biological tissue by matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS). MALDI-IMS is a powerful analytical technique capable of generating ~ 50-100 micrometer resolution images that can be filtered by mass, directly from biological tissue sections. Applications for the technique range from cataloging the distribution of bio-molecules and pharmaceuticals in tissues, to biomarker discovery, tumor classification, elucidation of pathogenesis, studies of developmental biology, etc. This proposal outlines a new technology aimed at improving MALDI-IMS analyses on several fronts. The basis of the technology is the construction of novel substrates designed to selectively extract, capture and enrich analyte(s) of interest from tissue, while preserving sample spatial resolution, in a format that will interface directly with the mass spectrometer. The methodology outlined here-in directly addresses the most recognized and consistent points of weakness in current MALDI-IMS analyses and will serve to enhance MALDI-IMS performance by providing more detail, balance and versatility to existing applications as well as providing exciting potential for expansion. The specific aims for this initial phase of the project target substrate construction and experimental procedure. Each aim is critical to proof- of-product feasibility and they allow for quantifiable evaluation and comparative performance with current, state-of-the-art MALDI-IMS technology. It is hypothesized here that the proposed technology will increase the detection thresholds of MALDI-IMS by enabling selectivity for targeted analyte(s) with simultaneous removal of interferents. It will increase sensitivity by allowing more appropriate conditions for analyte / matrix co-crystallization and it will increase data quality by providing an environment more optimal for mass spectrometry. It will stabilize the tissue image by presenting a substrate that will accurately lock-in the spatial integrity of the tissue at a resolution equal-to or greater- thn what is achievable by current protocols. It will increase intra-sample consistency and inter-sample reproducibility by decoupling the steps of analyst extraction and matrix deposition and providing a more systematic and optimized means for accomplishing these tasks. It will expand experimental capability by allowing sample manipulation without disturbing the spatial integrity. It will expand experimental capability by preserving the parent sample allowing for multiple, repetitive or divergent analyses to be performed on the same specimen. It will expand experimental capability by enabling the analysis of tissues of diverse shapes and forms and even allow for the analysis of living tissue. It will simplify experimental protocol by removing restrictions for cryogenically sliced tissue specimens and it will hopefully serve to expand participation in MALDI-IMS technology by lifting the need for specialized and expensive equipment. The prototype substrates are composed of a Duocel(R) reticulated vitreous carbon (RVC) foam combined with a porous polymer monolith. The materials used to develop these unique substrates are commercially available. The chemistry to be employed in plate construction is well understood and the reactants needed are commercially available. The tissue sample manipulations that will be attempted are documented in the literature. The preliminary data demonstrated here-in are encouraging.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    106250
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:106250\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    VIRGIN INSTRUMENTS CORPORATION
  • Organization Department
  • Organization DUNS
    606001134
  • Organization City
    MARLBOROUGH
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    017523056
  • Organization District
    UNITED STATES